{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:14:21Z","timestamp":1782472461357,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Data from Canadian populations regarding the burden of ASCVD are limited. Therefore, we describe the 5\u2010year period prevalence of ASCVD and subsequent major adverse cardiovascular event (MACE) outcomes among patients with ASCVD in Alberta, Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective, observational study was conducted by linking provincial health services data, vital statistics, and pharmaceutical dispenses data. Five\u2010year period prevalence of clinical ASCVD was captured between 2011 and 2016, and a cohort of adult patients with an initial clinical ASCVD event were identified between 2012 and 2016. One\u2010year incidence rates (IRs) of subsequent MACE outcomes were calculated as composite and individual measures. A subgroup of patients with acute myocardial infarction (AMI) as their index event was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 198\u2009573 patients (mean [standard deviation] age: 63.9 [15.6] years; 56.6% males) identified with clinical ASCVD between 2012 and 2016. Overall, the 5\u2010year period prevalence of ASCVD in Alberta was 89.9 per 1000 persons and the 1\u2010year IR for a primary MACE outcome was 6.15 (95% confidence interval [CI]: 6.03\u20136.26) per 100 person\u2010years. Among the ASCVD cohort, 9465 had an AMI as their index event and the IR for a primary MACE outcome was 14.30 (95% CI: 13.45\u201315.20) per 100 person\u2010years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study found that the prevalence of ASCVD and the rate of subsequent MACE outcomes 1\u2009year following the initial ASCVD event are substantial, particularly among patients with an AMI. Secondary prevention strategies aimed at lowering this risk are needed for patients with ASCVD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.23732","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T15:38:21Z","timestamp":1632929901000},"page":"1613-1620","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in <scp>Alberta, Canada<\/scp>: A real\u2010world evidence study"],"prefix":"10.1002","volume":"44","author":[{"given":"Guanmin","family":"Chen","sequence":"first","affiliation":[{"name":"Medlior Health Outcomes Research Ltd.  Calgary Alberta Canada"},{"name":"Libin Cardiovascular Institute, University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0640-9512","authenticated-orcid":false,"given":"Megan S.","family":"Farris","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd.  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Cowling","sequence":"additional","affiliation":[{"name":"Medlior Health Outcomes Research Ltd.  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Pinto","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina M.","family":"Rogoza","sequence":"additional","affiliation":[{"name":"Amgen Canada Inc.  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"MacKinnon","sequence":"additional","affiliation":[{"name":"Amgen Canada Inc.  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salimah","family":"Champsi","sequence":"additional","affiliation":[{"name":"Amgen Canada Inc.  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2015.06.006"},{"key":"e_1_2_11_3_1","unstructured":"Word Health Organization.Cardiovascular Diseases Fact Sheet. World Health Organization;2017.https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"e_1_2_11_4_1","unstructured":"Statistics Canada. (2020).Leading causes of death total population by age group.https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310039401."},{"key":"e_1_2_11_5_1","volume-title":"Table 1: Prevalence of Cardiovascular Disease (CVD) Risk, by Sex, Age and Cardiovascular Risk Factors, Household Population Aged 20 to 79, Canada Excluding Territories, 2007 to 2011","author":"Statistics Canada","year":"2017"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.137"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081629"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131358"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1178-6"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(93)90182-9"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109719"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205512"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.01.016"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.11.009"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00014"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13921"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1401529"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0157-z"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_11_25_1","volume-title":"Table 17\u201010\u20100005\u201001 Population Estimates on July 1st, by Age and Sex","author":"Statistics Canada","year":"2019"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180010"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014402"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx566"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13701"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.11.032"},{"key":"e_1_2_11_35_1","first-page":"191","article-title":"Safety and tolerability of PCSK9 inhibitors: current insights","volume":"12","author":"Kosmas CE","year":"2020","journal-title":"Clin Pharmacol"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2019.8.2.183"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2019.04.008"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.005"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23732","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clc.23732","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:24:40Z","timestamp":1693193080000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.23732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/clc.23732"],"URL":"https:\/\/doi.org\/10.1002\/clc.23732","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"2021-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}